Skip to main content
Article thumbnail
Location of Repository

Multi-marker testing for cancer: what can we learn from modern prenatal testing for Trisomy-21

By Erasmus Schneider and Gerald Mizejewski
Topics: Review
Publisher: Libertas Academica
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (1976a). “Estimates of maternal age-specifi c risks of Downsyndrome birth in women aged 34-41.”
  2. (1976b). “Risk of Down syndrome in relation to maternal age.”
  3. (1987). Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities.”
  4. (1999). Advances in the application of prostatespecifi c antigen in the detection of early-stage prostate cancer.” Semin Oncol 26(2): 140-9.Schneider et al 47
  5. (2000). An application of artifi cial neural networks in ovarian cancer early detection.
  6. (2002). An artifi cial neural network considerably improves the diagnostic power of percent free prostatespecifi c antigen in prostate cancer diagnosis: results of a 5-year investigation.”
  7. (2000). Assessment of risk of prostate cancer: algorithms for diagnosis, staging, and prognosis. Advanced therapy of prostate disease.
  8. (2004). Blood and urine markers for ovarian cancer: a comprehensive review.”
  9. (1998). CA 125: the past and the future.”
  10. (1995). Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses.”
  11. (1997). Combining ultrasound and biochemistry in fi rst-trimester screening for Down’s syndrome.”
  12. (1994). Comparision of digital rectal examination and serum prostate specifi c antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.”
  13. (1996). Dimeric inhibin A as a marker for Down’s syndrome in early pregnancy.”
  14. (1987). Estimating a woman’s risk of having a pregnancy associated with Down’s syndrome using her age and serum alpha-fetoprotein level.”
  15. (1995). Evaluation of percentage of free serum prostate-specifi c antigen to improve specifi city of prostate cancer screening.”
  16. (1998). Evaluation of prostAsure index in the detection of prostate cancer: a preliminary report.”
  17. (1998). Evaluation of the digital rectal examination as a screening test for prostate cancer.
  18. (2003). First and second trimester antenatal screening for Down’s syndrome: the results of the Serum,
  19. (1994). First trimester biochemical screening for Down’s syndrome.”
  20. (1988). First-trimester biochemical screening for Down syndrome.”
  21. (2004). First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the
  22. (2005). First-trimester or secondtrimester screening, or both, for Down’s syndrome.”
  23. (1994). Four-marker serum screening for Down’s syndrome.”
  24. (1995). Kennard A and Hackshaw AK
  25. (2005). New tumor markers: CA125 and beyond.”
  26. (1995). Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specifi city for early detection.” Cancer 76(10 Suppl):
  27. (2004). Preoperative sensitivity and specifi city for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colonystimulating factor using mixtures of multivariate normal distributions.”
  28. (2004). Prostate cancer detection in the prostate specifi c antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specifi c antigen on tumor detection and tumor aggressiveness.”
  29. (2001). Prostate-specifi c antigen-based early detection of prostate cancer—-validation of screening without rectal examination.”
  30. Rotterdam section of the European Randomized Study of Screening for
  31. (1989). Screening for Down syndrome.”
  32. (2005). Screening for prostate cancer.”
  33. (2005). Test Detects Down Syndrome Early.” Forbes Retrieved
  34. (2005). The Down Dilemma.” Time Retrieved
  35. (2004). Three biomarkers identifi ed from serum proteomic analysis for the detection of early stage ovarian cancer.”
  36. (2001). Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0-3.9 ng/ml).”
  37. (2002). Use of proteomic patterns in serum to identify ovarian cancer.”

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.